ESPAUR 2025: antibacterial resistance and the emergence of Candidozyma auris in England

The latest ESPAUR report (2024–2025) paints a sobering picture of AMR in England. While prescribing practices have improved in some areas, the resistant infections are increasing, and new threats like Candidozyma auris are emerging.

Continue reading

Farewell 2024 – ESPAUR helps us to set priorities for 2025

As we bid farewell to 2024, a time for reflection, objective setting, and the odd new years resolution to break early in 2025. The latest ESPAUR report was published a few months ago, and helps us to set some priorities for 2025 and beyond. As ever, there’s a mixture of good news and bad news in the report, but mostly I’m grateful that we have sufficient data and co-ordination to give us this level of detail about the current and emerging threats related to HCAI and AMR in the UK.

Continue reading